HomeRelapsing remitting MS

  • Recent study investigated RRMS to SPMS progression in MS patients

    • June 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • SPMS patients have higher cognitive decline than RRMS patients, study reports

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • EMD Serono Highlights Commitment to Advance MS Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018

    • April 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Beta-interferon & Glatiramer acetate pose low infection risks to MS patients, study reinforces

    • April 13, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Mylan acquires rights for new MS drug

    • April 11, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Mavenclad (cladribine) approved for Active RMS in UAE

    • April 10, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Mother to fly to Mexico for Stem cell MS treatment

    • April 9, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NICE denies Ocrelizumab for RRMS in UK

    • April 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Roche Acquires regenerative MS therapy program focused on remyelination

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NATCO launches generic version of Aubagio for MS in INDIA

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • 1
  • 2